Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
NCT07287098 · Breast Neoplasms
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms
NCT07060989 · Advanced Solid Tumors
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
Lexington, Kentucky
Cleveland, Ohio
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions